Drug details

Aliqopa (copanlisib for injection, for intravenous use)

type of Antineoplastics PI3K Inhibitors

Aliqopa (copanlisib) for injection is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

This drug may have the following side effects:

• diarrhea,
• low platelet count (thrombocytopenia),
• high blood sugar (hyperglycemia),
• decreased general strength and energy,
• high blood pressure (hypertension),
• low white blood cell count (leukopenia, neutropenia),
• nausea,
• lower respiratory tract infections,
• swelling and sores inside the mouth,
• vomiting, and rash.

The following drugs are related to Aliqopa, either as a replacement or used together:

• Adcetris (brentuximab vedotin)
• Beleodaq (belinostat for injection for intravenous use)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Gazyva (obinutuzumab injection)
• Imbruvica (ibrutinib capsules)
• Remicade (infliximab)
• Jaypirca (pirtobrutinib tablets)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Lunsumio (mosunetuzumab-axgb injection)
• Poteligeo (mogamulizumab-kpkc injection)
• Udenyca (pegfilgrastim-cbqv injection)
• Rituxan (rituximab)
• Ukoniq (umbralisib tablets)